Atjaunināt sīkdatņu piekrišanu

E-grāmata: New Approach for Drug Repurposing Part A

Volume editor (Department of Biosciences, School of Science, Indrashil University, Rajpur, Mehsana, India)
  • Formāts - EPUB+DRM
  • Cena: 156,48 €*
  • * ši ir gala cena, t.i., netiek piemērotas nekādas papildus atlaides
  • Ielikt grozā
  • Pievienot vēlmju sarakstam
  • Šī e-grāmata paredzēta tikai personīgai lietošanai. E-grāmatas nav iespējams atgriezt un nauda par iegādātajām e-grāmatām netiek atmaksāta.

DRM restrictions

  • Kopēšana (kopēt/ievietot):

    nav atļauts

  • Drukāšana:

    nav atļauts

  • Lietošana:

    Digitālo tiesību pārvaldība (Digital Rights Management (DRM))
    Izdevējs ir piegādājis šo grāmatu šifrētā veidā, kas nozīmē, ka jums ir jāinstalē bezmaksas programmatūra, lai to atbloķētu un lasītu. Lai lasītu šo e-grāmatu, jums ir jāizveido Adobe ID. Vairāk informācijas šeit. E-grāmatu var lasīt un lejupielādēt līdz 6 ierīcēm (vienam lietotājam ar vienu un to pašu Adobe ID).

    Nepieciešamā programmatūra
    Lai lasītu šo e-grāmatu mobilajā ierīcē (tālrunī vai planšetdatorā), jums būs jāinstalē šī bezmaksas lietotne: PocketBook Reader (iOS / Android)

    Lai lejupielādētu un lasītu šo e-grāmatu datorā vai Mac datorā, jums ir nepieciešamid Adobe Digital Editions (šī ir bezmaksas lietotne, kas īpaši izstrādāta e-grāmatām. Tā nav tas pats, kas Adobe Reader, kas, iespējams, jau ir jūsu datorā.)

    Jūs nevarat lasīt šo e-grāmatu, izmantojot Amazon Kindle.

New approach for drug repurposing represents drug discovery and development which is a tedious process that requires 10-15 years of time, investments up to $1-2 billion, and have high risk of failure to enter into market for clinical applications. As the drugs has to pass through number of developmental phase, the likelihood for a drug to be approved from phase I clinical trial to United States of Food and Drug Administration (USFDA) approval is less than 10%. More than 90% of drugs failed in due to toxicity, efficacy and clinical trials. Drug repurposing is one of the roadway to accelerating drug discovery and development for treating disease and thus to providing better quality of life. This volume covers an overview of drug repurposing, novel methods, mechanism of action, lab on chip for drug repurposing, computational biology, system biology, artificial intelligence and machine learning for drug repurposing, target identification, target mining, high throughput drug screening, clinical trial of repurposed drug, repurposed biologics, and regulatory consideration and intellectual property right of repurposed drug. This volume highlights a number of aspects of the drug repurposing that can help the basic understanding of students, researchers, clinicians, entrepreneurs, and stakeholders to perform their research with great interest.
Preface
Vijai Singh
1. An introduction to drug repurposing
Vijai Singh
2. New approaches for drug repurposing
Govinda Raj and Deepak Balaji Thimiri Govindaraj
3. Reimagining old drugs with new Tricks:Mechanism, strategies and notable success in drug repurposing for neurological disorders
Pravir Kumar, Samuel Raj, Rashmi K. Ambasta, Neetu Rani, Aastha Kaushik, Shefali Kardam and Sonika Kag
4. Lab-on-chip for testing of repurposed drug
Alok Pandya
5. Computational biology approaches for drug repurposing
Mustafeez Mujtaba Babar
6. Synergizing Drug Repurposing and Target Identification for Neurodegenerative Diseases
Pravir Kumar, Mehar Sahu, Shrutikeri Vashishtha, Neha Kukreti, Ashima Gulia, Aashish Russell and Rashmi K. Ambasta
7. Artificial Intelligence and ML for drug repurposing
Anil G. Jegga and Sudhir Ghandikota
8. Genomic approaches for drug repurposing
Vijai Singh
9. Systems biology approaches for drug repurposing
Ajay Kumar I
10. High-throughput screening for drug repurposing
Sunday N. Okafor, Eze Chinecherem and Ahuchaogu Ikenna
11. Approaches of pre-clinical and clinical trials of repurposed drug
Ajay Kumar I
12. Repurposing of biologics and biopharmaceuticals
Ajay Kumar I
13. Innovative Target Mining Stratagems to Navigate Drug Repurposing Endeavours
Saraswathy Ganesan Rajalekshmi
14. Regulatory considerations and intellectual property right of repurposed drug
Mustafeez Mujtaba Babar
Dr Vijai Singh is a Professor and Dean (Research & Innovation) at School of Sciences, Indrashil University, Rajpur, Mehsana, Gujarat, India. He was an Associate Professor in the Department of Biosciences, School of Sciences, Indrashil University, Rajpur, Mehsana, Gujarat, India. Prior this this, he was an Assistant Professor in the Department of Biological Sciences and Biotechnology at the Institute of Advanced Research, Gandhinagar, India and also an Assistant Professor in the Department of Biotechnology at the Invertis University, Bareilly, India. Prior to that, he was a Postdoctoral Fellow in the Synthetic Biology Group at the Institute of Systems and Synthetic Biology, Paris, France and School of Energy & Chemical Engineering at the Ulsan National Institute of Science and Technology, Ulsan, South Korea. He received his Ph.D. in Biotechnology from the National Bureau of Fish Genetic Resources, Uttar Pradesh Technical University, Lucknow, India with a research focus on the development of molecular and immunoassays for diagnosis of Aeromonas hydrophila. His research interests are focused on building novel biosynthetic pathways for production of medically and industrially important biomolecules. Additionally, his laboratory is working on CRISPR-Cas9 tools for genome editing. He has more than 11 years of research and teaching experience in synthetic biology, metabolic engineering, bioinformatics, microbiology, and industrial microbiology. He has published 100 articles, 70 chapters, 15 books and 3 patents. He serves as an associate editor, editorial board member, and reviewer of several peer-reviewed journals. He is also a member of the Board of Study and Academic Council of Indrashil University and is the Member Secretary of the Institutional Biosafety Committee (IBSC) at the same University.